| abstract |
Use as pharmaceuticals of compounds of Formula (IV), where W is halogen or a halogen-containing group; X is N or N = O; and R is selected from: i) R2-NH-R1-Z- where Z is NH, S, O, or CH2; R1 is a C1 to C4 alkyl group; and R2-NH- is a group resistant to dealkylation in vivo; or ii) formula (a) where Z and R1 are as described in (i) above, and formula (b) is a group resistant to dealkylation in vivo; or iii) R4-Ar-Z- where Z is as described in (i) above; Ar is a substituted or unsubstituted aromatic ring structure; and R4 is a planar or non planar, alkyl or cycloalkyl substituent on the 5' position of the aromatic ring Ar, and pharmaceutically acceptable salts thereof. |